Willis BS, Mongeon K, Dry H, Neveras IL, et al. Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia 2024 Sep 16. doi: 10.1038/s41375-024-02401.
PMID: 39284898